Home › Research › Drug development
Systematic identification of risk factors and drug repurposing options for Alzheimer's disease
Chong Wu, Lang Wu, Jingshen Wang, Lifeng Lin, Yanming Li, Qing Lu, Hong-Wen Deng. Alzheimer's & dementia (New York, N. Y.), 2021-03-03
Topic: Drug trials: efficacy and safety
There was strong evidence of a causal association between glioma risk, reduced trunk fat-free mass, lower education levels, lower intelligence and a higher risk of AD. For 31 investigated treatments (such as antihypertensive drugs), we found limited evidence for their associations. MR found robust evidence of causal associations between glioma, trunk fat-free, and AD. Our study also confirms that higher educational attainment and higher intelligence are associated with a reduced risk of AD.
Key findings
- There was strong evidence of a causal association between glioma risk, reduced trunk fat-free mass, lower education levels, lower intelligence and a higher risk of AD.
- For 31 investigated treatments (such as antihypertensive drugs), we found limited evidence for their associations.
- MR found robust evidence of causal associations between glioma, trunk fat-free, and AD.
- Our study also confirms that higher educational attainment and higher intelligence are associated with a reduced risk of AD.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 25 of the 56 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33718584) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 25 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 25 of the 56 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Wu, C., Wu, L., Wang, J., Lin, L., Li, Y., Lu, Q., et al. (2021). Systematic identification of risk factors and drug repurposing options for Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1002/trc2.12148
Vancouver
Wu C, Wu L, Wang J, Lin L, Li Y, Lu Q, et al. Systematic identification of risk factors and drug repurposing options for Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2021. doi:10.1002/trc2.12148. PMID: 33718584.
BibTeX
@article{wu2021-33718584,
author = {Wu, Chong and Wu, Lang and Wang, Jingshen and Lin, Lifeng and Li, Yanming and Lu, Qing and Deng, Hong-Wen},
title = {{Systematic identification of risk factors and drug repurposing options for Alzheimer's disease}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2021},
doi = {10.1002/trc2.12148},
pmid = {33718584},
url = {https://doi.org/10.1002/trc2.12148}
}
Related studies in Drug development
Also tagged “metabolic-syndrome”
304 studies in the library carry the topic tag “metabolic-syndrome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 304 tagged studies.